Sun Pharma Acquires Rights To Trademarks Of Three Diabetes Drug Brands In India From AstraZeneca

Drug major Sun Pharma on Friday said it has acquired the rights to trademarks of diabetes drug Dapagliflozin under brands Oxra, Oxramet and Oxraduo in India from AstraZeneca Pharma India's parent company."Sun Pharma has now acquired the rights to trademarks Oxra, Oxramet and Oxraduo in India from AstraZeneca AB, Sweden, parent company of AstraZeneca Pharma India Limited, with effect from May 28, 2021," Sun Pharma said in a regulatory filing.Sun Pharma said it has also taken a patent license to manufacture and commercialise Dapagliflozin and Dapagliflozin with Metformin combination in India from AstraZeneca AB with effect from May 28, 2021, the filing added. Consequently, AstraZeneca India and Sun Pharma have discontinued their existing distribution services agreement signed in 2016, for the distribution of Dapagliflozin.Under the said agreement, AstraZeneca India had granted rights to Sun Pharma to promote and distribute Dapagliflozin under the brand name Oxra. Sun Pharma also gained the rights to promote and distribute the combination of Dapagliflozin with Metformin under the brand name Oxramet and the combination of Dapagliflozin and Saxagliptin under the brand name Oxraduo.Both the companies have now entered into a transition supply agreement. Under the transition supply agreement, AstraZeneca India will supply Dapagliflozin and the combination of Dapagliflozin with Metformin to Sun Pharma until such period of time as mutually agreed between the parties, post which all supplies to Sun Pharma from AstraZeneca India shall cease.AstraZeneca India said it will continue to independently market Dapagliflozin, the combinations of Dapagliflozin and Metformin as well as Dapagliflozin and Saxagliptin in India under the brand names Forxiga Xigduo and Qtern respectively.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!